Helio Genomics Announces Strategic Commercial Partnership with Syneos Health® to Accelerate Nationwide Adoption of HelioLiver™, A Breakthrough AI-Powered Blood Test for Early Liver Cancer Detection

Syneos Health’s proven commercialization expertise to engage healthcare providers and expand access to HelioLiver™ for high-risk patients in the United States IRVINE, Calif., May 19, 2026 /PRNewswire/ — Helio Genomics, a leading AI-powered TechBio company focused on revolutionizing early…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks